BioNTech, founded by Turkish immigrants to Germany, and its US partner Pfizer on Tuesday announced starting of clinical study “to evaluate safety tolerability and immunogenicity of an Omicron-based vaccine candidate.” In a statement, the two companies announced the launching of a clinical study saying that it will be carried out on “healthy adults 18 through...
The CAD is big and its financing is bad!
To what extent does the misery index influence voters’ choices?
AI and beyond
Budget deficit risk of around 7% of GDP
Tourism revenues rise higher than the number of tourists
Need for anchor
Patents with technological advances in the automotive ecosystem
Let’s estimate FX rates…
Inflation soared while the policy rate was lowered
Famous banks’ election expectations
Energy and gold don’t explain the CAD
Levent Kafkasli becomes GM of GAP Insaat
Global tension: Is it decision time for Turkey?
When you don’t learn from a mistake from 30 years ago
UNDP sends containers to the quake-hit region
Annualized foreign trade deficit tripled in 1.5 years
KKM, liraization: Fiddlesticks!
January 26, 2022January 26, 2022by CommentaryIn Daily News
Pfizer-BioNTech begins clinical studies on Omicron-based vaccine
January 18, 2022January 18, 2022by Beste KaraIn Daily News
Fourth mRNA booster does not fully protect against omicron
The mRNA vaccine booster shots from Pfizer-BioNTech or Moderna are partially effective in defending against the Omicron variant of the coronavirus. They are safe and produce substantial antibodies, according to the preliminary results of research conducted by Sheba Medical Center in Israel. The trial showed that one week after people received the booster shot from...